IMA earnings analysis
What we found in IMA's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
ImageneBio, Inc. reported a net loss of $10.6 million for Q1 2026, increasing from a $6.1 million loss in Q1 2025. The company reported no revenue during the quarter, consistent with analyst expectations, while significantly ramping up both research and development and general administrative expenses. The company's cash position remains strong following a $30 million private placement in April 2026 and should support operations into 2028.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Net Loss Increased
- The net loss for Q1 2026 was $10.6 million, compared to a loss of $6.1 million in Q1 2025.
- No Revenue Generated
- ImageneBio reported no revenue for the quarter, consistent with previous performance.
- Increased Operating Expenses
- Total operating expenses were $12.1 million for Q1 2026, up from $6.8 million in Q1 2025.
- Cash Position Strong
- As of March 31, 2026, the company had $117.2 million in cash, cash equivalents and marketable securities.
- Significant R&D Investment
- Research and development expenses increased to $5.96 million for Q1 2026, up from $4.04 million in Q1 2025.
- Private Placement Funding
- The company secured $30.0 million in gross proceeds from a private placement in April 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Increased Operating Losses
- For the three months ended March 31, 2026, the operating loss was $12.08 million compared to $5.99 million in Q1 2025.
- Material Weakness in Internal Control
- The company identified a material weakness in internal control over financial reporting that remains unresolved as of Q1 2026.
- No Revenue Generation
- The company continues to generate no revenue from product sales, impacting future growth potential.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-10.619
What they said about what is next.
No forward guidance was provided in the filing.
The filing reads worse than the one before it.
What came before.
- 10-K · March 10, 2026
- ImageneBio (formerly Ikena Oncology) is a clinical-stage biopharmaceutical company focused on IMG-007, a non‑depleting anti‑OX40 monoclonal antibody being developed initially for atopic dermatitis (AD). The 10‑K…
- 10-K · March 6, 2025
- Ikena Oncology has shifted from stand-alone drug development to pursuing strategic alternatives, signing a merger agreement with Inmagene in December 2024 (expected to close mid-2025). The company retains a lead…
- 10-K · March 12, 2024
- Ikena Oncology is a clinical-stage targeted oncology company advancing TEAD inhibitor IK-930 (Phase 1 monotherapy dose escalation with initial anti-tumor activity reported November 2023) and RAS-pathway candidate IK-595…
- 10-Q · November 9, 2023
- Ikena Oncology reported Q3 2023 collaboration revenue of $1,185,000 (down from $6,402,000 in Q3 2022) while operating expenses fell to $20,688,000 from $24,278,000, leaving a Q3 net loss of $17,343,000 (essentially flat…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing IMA makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever